Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Br J Haematol. 2021 May 15;193(5):951–960. doi: 10.1111/bjh.17406

Fig 2.

Fig 2.

Chimaerism and cord engraftment. (A) Median per cent myeloid chimaerism; (B) cumulative incidence of cord engraftment [cord absolute neutrophil count (ANC) ≥ 500/μl] and full cord myeloid chimaerism; (C) median per cent T-cell chimaerism; (D) cumulative incidence of full cord T-cell chimaerism; (E) cumulative incidence of cord engraftment (cord ANC ≥ 500/μl) by haplo-vs-cord KIR ligand incompatibility (E) and by haplo-vs-cord KIR ligand incompatibility and cord human leucocyte antigen match to the recipient (F).